Regeneron Pharmaceuticals Inc

REGN is in a modest pullback within its longer-term uptrend. Short-term technicals show price under declining 9/20 EMAs and RSI drifting lower, suggesting room for mean-reversion toward the rising 50-day SMA around the 751 area. The medium-term stage 2 uptrend remains intact, so buying on a pullback into the 780–750 support zone is preferred. Execution should be deferred (stalk) for confirmation of support and improving momentum near the 50-day SMA before initiating new exposure.

• ↑Q2 revenue $4.3B (+17% YoY) and Dupixent sales $6B (+38% YoY)
• ↑Pipeline of ~50 active trials, with oncology and genetic therapies advancing
• ↓Dupixent dependency creates revenue risk if growth slows